Recursion Prescribed drugs, Inc. (NASDAQ:RXRX – Get Score) Director Blake Borgeson offered 8,885 shares of the agency’s inventory in a transaction that occurred on Tuesday, December thirteenth. The inventory was offered at a mean worth of $8.96, for a complete transaction of $79,609.60. Following the transaction, the director now instantly owns 7,637,157 shares within the firm, valued at $68,428,926.72. The sale was disclosed in a doc filed with the Securities & Change Fee, which is out there on the SEC web site.
Blake Borgeson additionally just lately made the next commerce(s):
- On Tuesday, November twenty ninth, Blake Borgeson offered 8,885 shares of Recursion Prescribed drugs inventory. The inventory was offered at a mean worth of $8.75, for a complete transaction of $77,743.75.
- On Wednesday, November sixteenth, Blake Borgeson offered 17,770 shares of Recursion Prescribed drugs inventory. The inventory was offered at a mean worth of $11.12, for a complete transaction of $197,602.40.
Recursion Prescribed drugs Buying and selling Down 7.2 %
Recursion Prescribed drugs inventory traded down $0.66 throughout mid-day buying and selling on Thursday, reaching $8.47. The corporate had a buying and selling quantity of 1,559,300 shares, in comparison with its common quantity of 1,123,920. Recursion Prescribed drugs, Inc. has a fifty-two week low of $4.92 and a fifty-two week excessive of $20.15. The corporate has a market cap of $1.61 billion, a P/E ratio of -6.34 and a beta of -0.63. The enterprise has a fifty day easy shifting common of $10.16 and a 200 day easy shifting common of $9.69.
Wall Road Analyst Weigh In
A number of analysis corporations just lately issued studies on RXRX. SVB Leerink decreased their worth goal on shares of Recursion Prescribed drugs from $10.00 to $9.00 and set a “market carry out” score on the inventory in a analysis report on Tuesday, October twenty fifth. KeyCorp started protection on shares of Recursion Prescribed drugs in a analysis report on Thursday, September fifteenth. They set an “chubby” score and a $20.00 worth goal on the inventory. Lastly, The Goldman Sachs Group elevated their worth goal on shares of Recursion Prescribed drugs from $8.00 to $9.00 and gave the inventory a “impartial” score in a analysis report on Wednesday, November ninth.
Institutional Buying and selling of Recursion Prescribed drugs
Quite a few hedge funds have just lately added to or decreased their stakes in RXRX. State Road Corp boosted its place in Recursion Prescribed drugs by 114.3% within the third quarter. State Road Corp now owns 4,555,759 shares of the corporate’s inventory valued at $48,473,000 after shopping for a further 2,430,027 shares within the final quarter. BlackRock Inc. lifted its holdings in shares of Recursion Prescribed drugs by 18.5% in the course of the third quarter. BlackRock Inc. now owns 9,767,040 shares of the corporate’s inventory value $103,921,000 after buying a further 1,525,258 shares in the course of the interval. Vanguard Group Inc. lifted its holdings in shares of Recursion Prescribed drugs by 19.9% in the course of the third quarter. Vanguard Group Inc. now owns 8,380,986 shares of the corporate’s inventory value $89,174,000 after buying a further 1,393,519 shares in the course of the interval. Platinum Funding Administration Ltd. lifted its holdings in shares of Recursion Prescribed drugs by 48.0% in the course of the first quarter. Platinum Funding Administration Ltd. now owns 2,136,604 shares of the corporate’s inventory value $15,298,000 after buying a further 692,741 shares in the course of the interval. Lastly, FMR LLC lifted its holdings in shares of Recursion Prescribed drugs by 32.2% in the course of the second quarter. FMR LLC now owns 2,835,852 shares of the corporate’s inventory value $23,084,000 after buying a further 690,213 shares in the course of the interval. Institutional buyers and hedge funds personal 54.16% of the corporate’s inventory.
Recursion Prescribed drugs Firm Profile
(Get Score)
Recursion Prescribed drugs, Inc operates as a clinical-stage biotechnology firm, engages within the decoding biology by integrating technological improvements throughout biology, chemistry, automation, knowledge science, and engineering to industrialize drug discovery. The corporate develops REC-994, which is in Section IIa medical trial to deal with cerebral cavernous malformation; REC-2282 for the remedy of neurofibromatosis kind 2; REC-4881 to deal with familial adenomatous polyposis; and REC-3599, which is in Section I medical trial to deal with GM2 gangliosidosis.
See Additionally
This prompt information alert was generated by narrative science know-how and monetary knowledge from MarketBeat to be able to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to contact@marketbeat.com.
Earlier than you contemplate Recursion Prescribed drugs, you will wish to hear this.
MarketBeat retains observe of Wall Road’s top-rated and finest performing analysis analysts and the shares they advocate to their purchasers each day. MarketBeat has recognized the 5 shares that prime analysts are quietly whispering to their purchasers to purchase now earlier than the broader market catches on… and Recursion Prescribed drugs wasn’t on the record.
Whereas Recursion Prescribed drugs presently has a “Maintain” score amongst analysts, top-rated analysts imagine these 5 shares are higher buys.
View The 5 Shares Right here
